Generated: April 23, 2017
|Title:||Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use|
|Abstract:||Aromatic sulfonamides with a saturated heterocycle fused thereto are carbonic anhydrase inhibitors useful in the treatment of elevated intraocular pressure.|
|Inventor(s):||Baldwin; John J. (Gwynedd Valley, PA), Ponticello; Gerald S. (Lansdale, PA), Christy; Marcia E. (Collegeville, PA)|
|Assignee:||Merck & Co., Inc. (Rahway, NJ)|
|Filing Date:||Jun 15, 1988|
|Claims:||1. A compound of structural formula: ##STR27## the individual diastereomers, the individual enantiomers or mixtures thereof, or a ophthalmologically acceptable salt thereof, wherein: |
X is --S--, --SO--, or --SO.sub.2 --;
Y is --S--,
m is 1;
(b) phenyl either unsubstituted or substituted with one or more of
(2) C.sub.1-3 alkoxy,
(3) R.sup.17 R.sup.18 N-C.sub.1-5 alkyl, wherein R.sup.17 and R.sup.18 are independently selected from:
(i) hydrogen or
(ii) C.sub.1-5 alkyl, or taken together with the nitrogen to which they are attached form a heterocycle selected from morpholine, piperidine, pyrrolidine, and piperazine,
(d) .dbd.O; or
(e) --NR.sup.17 R.sup.18
(d) NR.sup.17 R.sup.18
(e) --C.sub.1-5 alkyl
(f) R.sup.17 R.sup.18 N-C.sub.1-3 alkyl
(g) phenyl-C.sub.1-3 alkyl, wherein the phenyl is either unsubstituted or substituted with one or more of
(2) C.sub.1-3 alkoxy, or
(a) hydrogen, or
(b) C.sub.1-5 alkyl;
R.sup.15 and R.sup.16 are alkyl groups joined together to form a spirocycle of 3-7 members.
2. An ophthalmological formulation for the treatment of ocular hypertension comprising an ophthalmologically acceptable carrier and an effective ocular antihypertensive amount of a compound of claim 1.
3. A method of treating elevated intraocular pressure comprising the administration to a patient in need of such treatment of an effective intraocular pressure lowering amount of the compound of claim 1.
4. A method of treating ocular hypertension comprising topical ocular administration to a patient in need of such treatment of an effective ocular antihypertensive amount of a compound of claim 1.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.